Cambrian Bio to Present Two Posters on ATX-304 at the American Diabetes Association 86th Scientific Sessions
Cambrian Bio, a clinical-stage drug development company with pipeline therapies targeting critical metabolic pathways that decline with age, today announced that two posters featuring data on one of its lead pipeline therapeutics, ATX-304, will be presented at the American Diabetes Association’s (“ADA”) 86th Scientific Sessions, taking place June 5-8, 2026, at the Ernest N. Morial Convention Center in New Orleans, Louisiana. Cambrian Bio will present data from its Phase 1b clinical study of ATX-304 in participants with obesity and prediabetes, as well as further research into the mechanism of action of ATX-304.
